Speaker illustration

Doctor Michal Laufer-Perl

Tel Aviv Sourasky Medical Center, Tel Aviv (Israel)

Member of:

European Society of Cardiology
Heart Failure Association

My name Is Michal Laufer Perl (MD, MHA) and I'm the director of the cardio-vascular clinics and practicing in Heart Failure and Cardio-oncology in Tel Aviv Sourasky Medical Center in Israel. I've established the cardio-oncology clinic in our facility in 2016 which today is the largest clinic in Israel with 1300 visits per year. As part of the cardio-oncology clinic we established a prospective registry (ICOR) evaluating all the patients referred to the cardio-oncology clinics and counting for over 600 patients with a number of studies already published and presented in international conferences.

The predictive value of routine troponin measurements in patients treated with immune checkpoint inhibitors

Event: Heart Failure 2024

Topic: Cardio-Oncology

Session: How to improve prognosis in cardio-oncology

Thumbnail

Atrial mechanics in heart failure with preserved ejection fraction: effect of a no-implant interatrial shunt

Event: Heart Failure 2024

Topic: Heart Failure with Preserved Ejection Fraction (HFpEF)

Session: Chronic heart failure - pathophysiology and mechanisms 10

Thumbnail

Association between beta-1-blockers and reduced efficacy of pembrolizumab in non-small cell lung cancer

Event: Heart Failure 2023

Topic: Cardio-Oncology

Session: ePosters in cardiovascular disease in special populations 2

Thumbnail

The prognostic value of sodium-glucose co-transporter-2 inhibitors therapy among patients with cancer and diabetes mellitus, treated with immune checkpoint inhibitors

Event: Heart Failure 2023

Topic: Cardio-Oncology

Session: ePosters in cardiovascular disease in special populations 1

Thumbnail

Multi-centre clinical outcomes of a no-implant interatrial shunt for heart failure with preserved and reduced ejection fraction: update from the ALLEVIATE-HF program

Event: Heart Failure 2023

Topic: Multidisciplinary Interventions

Session: Chronic heart failure - diagnostic methods

Thumbnail

COVID-19 vaccine-induced myocarditis vs. Immune checkpoint inhibitor-induced myocarditis - Same but different?

Event: ESC Congress 2022

Topic: Cardio-Oncology

Session: COVID-19 and cardiovascular disease in special populations

Thumbnail

Valvular changes following anthracycline therapy: is it time to look beyond ejection fraction?

Event: ESC Congress 2022

Topic: Cardio-Oncology

Session: Cardio-oncology 1

Thumbnail

High neutrophil-to-lymphocyte ratio as an early sign for cardiotoxicity in breast cancer patients treated with anthracycline

Event: Heart Failure 2022

Topic: Cardio-Oncology

Session: Heart Failure ePosters - focus on Comorbidities and special population

Thumbnail

Right ventricle strain changes in patients with breast cancer during anthracycline therapy

Event: ESC Congress 2021 - The Digital Experience

Topic: Cardio-Oncology

Session: Cardiovascular Disease in Special Populations ePosters

Thumbnail

Repetitive milrinone therapy in ambulatory advanced heart failure patients

Event: Heart Failure 2021

Topic: Heart Failure with Reduced Ejection Fraction (HFrEF)

Session: ePoster session

Thumbnail